Safety
The incidence of any AEs observed in the carotegrast methyl alone group was one out  of 20 (5.0%), and in the coadministration of carotegrast methyl with rifampicin group the incidence was five out of 20 (25.0%). The incidence of AEs for which a causal relationship with the study drug could not be ruled out was one out of 20 (5.0%) in the carotegrast methyl alone group and one out of 20 (5.0%) in the rifampicin combination group. AEs in the coadministration group with rifampicin for which a causal relationship with concomitant drug could not be ruled out occurred in two out of 20 subjects (10.0%). The only AE in the carotegrast methyl alone group was nausea (one of 20 subjects), while AEs in the coadministration group with rifampicin were blood bilirubin increased (two of 20 subjects), C-reactive protein increased (two of 20 subjects), and viral upper respiratory tract infection (one of 20 subjects). All AEs were mild in severity. AEs for which a causal relationship with the study drug could not be ruled out were nausea in one out of 20 (5.0%) in the carotegrast methyl alone group and viral upper respiratory tract infection in one out of 20 (5.0%) in the rifampicin combination group. In the coadministration group with rifampicin, the AE for which a causal relationship with concomitant drugs could not be ruled out was blood bilirubin increased, which occurred in two out of 20 subjects (10.0%). Neither deaths nor the other SAEs were reported.